12月22日 - ** 制药公司Cytokinetics CYTK.O股价盘前上涨2%，至63.93美元
** 美国食品和药物管理局周五批准了 (link) Cytokinetics 的口服药物，用于治疗一种名为阻塞性肥厚型心肌病的罕见心脏病。
** 这款备受关注的药物被命名为 Myqorzo，将 与百时美施贵宝的BMY.N Camzyos 竞争。
** Guggenheim Partners 分析师 Seamus Fernandez 说："我们认为，BMY 的 Camzyos 与 CYTK 的 Myqorzo 相比，将在 oHCM 领域保持市场份额第一的优势。
** 截至上一交易日收盘，CYTK股价年累计上涨33.3%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.